This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Boston Scientific's Symetis Buyout Boosts Structural Heart
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.
Medtronic's MyCareLink Data on Older Patients Found Positive
by Zacks Equity Research
Medtronic plc (MDT) recently released favorable data on its app-based remote cardiac monitoring.
Halyard Health Announces New Drainage System, Stock Down
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the availability of the Halyard Enteral Drainage System, a significant addition to the company's comprehensive portfolio of enteral feeding products.
Boston Scientific Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Natick, MA-based Boston Scientific Corporation (BSX) reached a new 52-week high of $26.76 on May 16, eventually closing a bit lower at $26.48.
Abbott Lab Well Poised on Strong EPD, St. Jude Integration
by Zacks Equity Research
On May 17, we issued an updated research report on Abbott Laboratories (ABT).
Genomic Health Q1 Results Weak, Cancer Test Business Strong
by Zacks Equity Research
On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).
Evolent Health (EVH) Prices 7M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $24.65 per share.
Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.
Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.